BusinessaTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle SocietyBy Nasdaq OMXSep 27, 2017, 12:01 PM UTC
BusinessaTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology PipelineBy Nasdaq OMXAug 14, 2017, 8:06 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual MeetingBy Nasdaq OMXApr 24, 2017, 12:02 PM UTC
BusinessaTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular DystrophyBy Nasdaq OMXApr 24, 2017, 11:30 AM UTC
